Good morning. It's July 26.

This week’s Digest has a lot to chew on: how to test for heavy metal toxins, a biotech picks a fight with cholesterol's reputation, a $100M wellness super app wants to combine it all, and a once-hyped well-funded longevity clinic chain just shut its doors, and it won't be the last.

The rundown for this week:

Let's get to it. 👇

Eternal, a venture-backed longevity clinic chain, is shutting down its San Francisco and New York locations at the end of the month - after raising $13 million to pair DEXA scans and VO2 max testing with physician-led care. CEO Alex Mather told members the company "was not able to build a sustainable business to support our long-term vision." More consolidation looks likely as bigger, better-capitalized players enter the space. Fitt Insider

Juno Bio raised $3.8 million and opened its first CLIA-certified sequencing lab built entirely for women's health - the Oakland facility brings vaginal microbiome and STI testing in-house instead of outsourcing it. The company says 67.5% of customers using its test had previously been misdiagnosed, underdiagnosed, or overdiagnosed by traditional care, with only 13% successfully treated - a startling miss rate that's fueling investor appetite for precision diagnostics in women's health. MedCity News

Medicare quietly started covering GLP-1 drugs for weight loss this month - the new GLP-1 Bridge Program, running July 1, 2026 through the end of 2027, covers Wegovy, Foundayo, and the KwikPen formulation of Zepbound at a flat $50 copay for beneficiaries prescribed the drugs specifically for weight loss. It's a pilot, but it's the first crack in Medicare's longstanding refusal to pay for weight-loss drugs - and a preview of what happens to the obesity-drug market once the country's largest insurer starts footing the bill. Ask a Patient

Colorectal cancer is now the leading cause of cancer death in adults under 50 - and diagnoses in the 20-49 age group are rising roughly 3% a year. Persistent bowel changes, rectal bleeding, dark stools, unexplained weight loss, and fatigue are the symptoms doctors say get dismissed most often in younger patients. ScienceDaily

A mismatch between your mitochondrial and nuclear DNA can quietly speed up aging - a new fruit fly study found mismatched mitonuclear genomes accelerate mitochondrial decline and shorten lifespan. The twist: a bit of dietary stress early in life reversed the damage, restoring normal mitochondrial function and longevity. Fight Aging!

For years, cardiologists have obsessed over LDL cholesterol as the number to lower if you want to avoid a heart attack. BioAge Labs is betting that inflammation deserves the same obsessive attention - and it just dosed the first patient in a trial built to test that bet directly.

The trial, called QUELL-CV, is a Phase 2 proof-of-concept study of BGE-102, an oral NLRP3 inflammasome inhibitor from BioAge, a publicly traded (Nasdaq: BIOA) biotech that builds its pipeline by targeting the biology of aging rather than starting from a single disease. NLRP3 is a protein complex inside immune cells that, when activated, drives the kind of chronic low-grade inflammation increasingly viewed as a major, modifiable driver of cardiovascular events - on par with elevated LDL, according to BioAge's own framing of the trial.

QUELL-CV will enroll roughly 160 adults with obesity, elevated systemic inflammation (hsCRP above 3 mg/L), and at least one additional cardiovascular risk factor, randomizing them across placebo and three doses of BGE-102 (30mg, 60mg, and 90mg, once daily). The trial builds on Phase 1 data in which the drug produced what BioAge describes as potential best-in-class reductions in hsCRP - a standard blood marker of systemic inflammation - while staying well tolerated across every dose tested.

The science breakdown:

Why it matters: Statins made LDL cholesterol a number ordinary people actually track and treat. If BGE-102 pans out, hsCRP - a far less mainstream biomarker - could get the same treatment: something your doctor checks, worries about, and prescribes a daily pill for. That's a meaningfully different way to think about heart disease prevention, and it's part of a broader shift in cardiometabolic medicine toward treating inflammation as a root cause of aging rather than a side effect of it. BioAge CEO Kristen Fortney has said the same NLRP3 target may have applications beyond the heart - potentially in ocular and CNS disease too, since BGE-102 is brain-penetrant.

👉 GlobeNewswire | Fierce Biotech

Mercury builds up in the body mostly from seafood - tuna, swordfish, and other larger fish absorb it from the ocean, and it doesn't leave your system quickly. Lead can still turn up in older plumbing, some imported spices, and paint in pre-1978 homes. Arsenic shows up in rice and certain groundwater. Cadmium comes from cigarette smoke, some fertilizers, and workplace exposure.

None of this comes with a warning label. Heavy metal buildup is usually silent - there's no single symptom that flags it, which is exactly why it's easy to go years without ever checking.

Superpower's Heavy Metal Toxins Test screens for lead, mercury, arsenic, and cadmium as part of its full biomarker panel, so you can see where your levels actually stand instead of guessing based on your diet or your zip code.

(This section contains an affiliate link - if you buy through it, we may earn a commission at no extra cost to you.)

In wellness right now, one app tracks your sleep, another counts your steps, your gym has its own membership, your nutrition advice comes from somewhere else, and your annual bloodwork sits in a completely different system. Nova Capital Enterprises and Metamorph think that fragmentation is the actual business opportunity.

The two firms announced a joint venture to launch a UAE-based wellness and longevity investment platform, backed by an initial $100 million pipeline they expect to grow beyond $200 million over time. Rather than backing isolated businesses, the plan is to invest across fitness, nutrition, recovery, preventive health, diagnostics, and social wellbeing - bundling them into one connected experience, with AI helping tailor programs and interpret health data along the way.

The bet is backed by Al Nasser Holdings, whose chairman framed it as a long-term commitment to a sector he expects to define the next generation of health, lifestyle, and human performance. Metamorph co-founder Manish Raniga described the shift more bluntly: from reactive services to preventive healthspan, from episodic consumption to continuous wellbeing, from fragmented offerings to integrated platforms.

Why this deal matters:

Whether this becomes the ‘Apple ecosystem’ of wellness is an open question. But the underlying wager is clear: as longevity capital gets bigger, expect more of it to chase integration - owning the whole stack - rather than funding yet another point solution.

👉 Longevity.Technology

Bryan Johnson, the tech-entrepreneur-turned-longevity-influencer behind Project Blueprint, revealed in July that he has autoimmune gastritis (AIG) - an incurable condition in which the immune system attacks the stomach's acid-producing cells. It affects fewer than 5% of people worldwide and isn't fatal on its own, but it's linked to a higher risk of stomach cancer.

Johnson, who has spent years and reportedly upward of $2 million a year running an elaborate self-experimentation protocol aimed at reversing his own biological age, attributed the diagnosis partly to years of poor eating and stress as a father of three. His plan for managing it, announced on social media, was somewhat more Bryan Johnson than "start a new medication": he says he intends to clone himself.

The stated rationale - a genetically identical body available as his "own blood boy," a subject for testing therapies, a source of organs for transplantation and young cells for injection - reads like satire. But Johnson has built his public persona on taking ideas like this seriously and literally. It's a useful reminder of how the same person can be both a legitimate source of real self-tracking data (his Blueprint protocol has evolved considerably this year, dropping rapamycin after side effects and adding low-dose lithium) and a walking example of how far personal biohacking can drift from anything resembling mainstream medical practice.

Why this is worth paying attention to: Johnson remains one of the most visible public faces of the longevity movement, for better or worse - Blueprint raised $60 million in 2025 from backers including Kim Kardashian, Naval Ravikant, and the Winklevoss twins, explicitly to productize his protocol for a mass audience. What he does with his own health, including the more theatrical parts, shapes public perception of what "biohacking" means, whether the field likes it or not.

👉 NewsNation

I thought all matcha tasted the same. Then I tried Pique’s Sun Goddess Matcha.

This ceremonial-grade matcha is smooth, vibrant, and naturally rich in L-theanine for calm, focused energy. No bitterness. No jitters. No crash.

Just clean energy and a simple ritual that makes mornings better. 🍵🌿

Get Up To 20% Off

Most of the mainstream brain-health conversation - drugs, biomarkers, clinical trials - defaults to treating the female brain like a smaller version of the male one. This book argues that's a mistake, and that the difference matters for anyone trying to think seriously about long-term cognitive health.

Dr. Lisa Mosconi directs the Women's Brain Initiative at Weill Cornell Medical College, where her research focuses on a stat most people don't know: nearly two-thirds of Alzheimer's patients are women. Her argument is that decades of brain research defaulted to treating women as "men with different reproductive organs," missing that the female brain ages on its own timeline - driven largely by the decline of estrogen, a hormone with real protective effects on brain metabolism.

The book walks through what happens to the brain across perimenopause and menopause, and lays out an evidence-based approach across diet, sleep, and stress reduction aimed at protecting cognitive health through that transition. It also tackles thornier territory - the hormone replacement therapy debate, environmental toxins, and the gut-brain connection - without pretending the science is more settled than it is.

Dense on mechanism, practical on application - and a useful counterweight to a field that still too often treats "brain health" as gender-neutral.

👉 Get The XX Brain

Blueberries decoded 👇

Ad slots are filling up fast. To promote your longevity / biohacking product to our niche audience, see the media kit and get in touch with Sebastian at [email protected]